In a landmark head-to-head analysis of real-world treatment outcomes, Johnson & Johnson announced today that patients with metastatic castration-sensitive prostate cancer (mCSPC) who were treated with Erleada® (apalutamide) experienced a 51% lower risk of death compared to those treated with darolutamide.
The findings, presented yesterday at the 36th Annual International Prostate Cancer Update, mark the first time these two leading androgen receptor inhibitors (ARIs) have been compared directly in a large-scale, real-world setting specifically for patients not receiving concurrent chemotherapy (docetaxel).
A Breakthrough in Survival Outcomes
The retrospective study analyzed nearly 1,750 patients treated in routine clinical practice between August 2022 and June 2025. According to the data, patients initiating Erleada without docetaxel showed a statistically significant survival advantage over those on darolutamide (hazard ratio [HR] 0.49; P=0.007) through 24 months of follow-up.
For patients with mCSPC, a stage where the cancer has spread beyond the prostate but still responds to hormone therapy, survival is the ultimate benchmark. The study found that 92.1% of patients in the Erleada group were alive at the two-year mark, a figure that reinforces the high efficacy seen in earlier clinical trials.
Read More: Johnson & Johnson’s Akeega® Moves Closer to EMA Approval for High-Risk Metastatic Prostate Cancer
Rigorous Methodology in the Absence of Clinical Trials
Because prospective, head-to-head clinical trials between approved drugs are often impractical and costly to conduct, researchers turned to “Real-World Evidence” (RWE). This study followed rigorous FDA-aligned methodologies, including “Inverse Probability of Treatment Weighting” (IPTW) to balance patient characteristics and ensure a fair comparison.
The analysis included 1,460 patients on Erleada and 287 on darolutamide. By adjusting for baseline differences, investigators were able to isolate the impact of the specific medication on patient survival.
Read More: Janssen Seeks Expanded Approval for Prostate Cancer Drug AKEEGA® in Europe
The Importance of “Docetaxel-Free” Regimens
A key highlight of the study was the focus on patients not receiving docetaxel. While docetaxel is a standard chemotherapy option, many patients and physicians prefer oral, “chemo-free” regimens to avoid the side effects associated with infusion-based chemotherapy, such as hair loss, severe fatigue, and immune suppression.
The data suggest that for patients opting for an ARI-only approach (combined with standard hormone therapy), Erleada may offer a superior survival profile compared to its competitor, darolutamide.
Looking Ahead
Prostate cancer remains a leading cause of death for men in the United States, with an estimated 36,000 deaths projected for 2026 alone. As roughly 40% of patients are classified as high-risk, the ability to select the most effective therapy early in the disease progression is vital.
Erleada was first approved by the FDA in 2018 and has since been prescribed to more than 325,000 patients worldwide. These latest findings build upon the Phase 3 TITAN trial, which originally established Erleada’s survival benefits.
As the oncology community moves toward more personalized medicine, this head-to-head analysis provides clinicians with a powerful new data point to guide treatment decisions for thousands of men battling advanced prostate cancer.
Last Modified:
